UNASSIGNED:基于免疫疗法的方法是对黑色素瘤患者具有潜在治疗益处的重要突破。粘蛋白1(MUC1)在黑素瘤中相对于正常细胞显著上调。据报道,MUC1影响癌细胞增殖,凋亡,入侵,和转移。本研究旨在探讨MUC1敲低对黑色素瘤细胞系B16F10生物学特性的影响,并评估MUC1是否是黑色素瘤疫苗开发的有效候选靶抗原。
未经批准:首先,慢病毒载体介导的短发夹RNA(shRNA)用于敲低B16F10细胞(shMUC1-B16F10细胞)中的MUC1。接下来,我们检查了上皮-间质转化(EMT),迁移,增殖能力,克隆形成,和shMUC1-B16F10细胞的细胞周期分布。最后,通过反复冻融shMUC1-B16F10细胞制备疫苗,并用于皮下免疫C57BL/6小鼠,然后在最后一次疫苗接种后10天使用B16F10细胞攻击。
未经证实:发现shMUC1抑制B16F10增殖和集落形成能力,诱导细胞周期停滞在G0/G1期,并调整EMT相关因子的表达。MUC1下调显著抑制B16F10疫苗在小鼠模型中对黑色素瘤的作用。与接种B16F10的小鼠相比,MUC1沉默的B16F10接种小鼠具有降低的自然杀伤(NK)细胞毒性,降低干扰素-γ(IFN-γ)的产生,抗MUC1抗体,穿孔素,颗粒酶B,和升高的肿瘤生长因子-β(TGF-β)水平。
UNASSIGNED:MUC1具有很强的黑色素瘤疫苗免疫原性,并诱导宿主的抗肿瘤反应。MUC1敲低抑制B16F10细胞疫苗的免疫活性和抗黑色素瘤作用,提示MUC1是黑色素瘤疫苗的重要候选靶抗原。
UNASSIGNED: Immunotherapy-based approaches are important breakthroughs with potential treatment benefits for melanoma patients. Mucin 1 (MUC1) is significantly upregulated in melanoma relative to normal cells. It has been reported that MUC1 influences cancer cell proliferation, apoptosis, invasion, and metastasis.The study aimed to explore the effect of MUC1 knockdown on the biological characteristics of the melanoma cell line B16F10 and evaluate whether MUC1 is an effective candidate target antigen for melanoma vaccine development.
UNASSIGNED: First, lentiviral vector-mediated short hairpin RNA (shRNA) was used to knockdown MUC1 in B16F10 cells (shMUC1-B16F10 cells). Next, we examined epithelial-mesenchymal transition (EMT), migration, proliferative capacity, clone formation, and distribution of cell cycle in shMUC1-B16F10 cells. Finally, the vaccine was prepared by repeated freeze-thawing of the shMUC1-B16F10 cells and used to subcutaneously immunize C57BL/6 mice, which were then challenged using B16F10 cells 10 days after the final vaccination.
UNASSIGNED: It was revealed that shMUC1 suppressed B16F10 proliferative and colony formation capacity, induced the arrest of cell cycle in the G0/G1 phase, and adjusted the expression of EMT-associated factors. MUC1 downregulation markedly suppressed the effect of B16F10 vaccine against melanoma in a mouse model. As compared with B16F10-vaccinated mice, B16F10-vaccinated mice in which MUC1 was silenced had reduced natural killer (NK) cytotoxicity, lower production of interferon-γ (IFN-γ), anti-MUC1 antibodies, perforin, granzyme B, and elevated tumor growth factor-β (TGF-β) level.
UNASSIGNED: MUC1 has strong melanoma vaccine immunogenicity, and induces the host\'s anti-tumor reaction. MUC1 knockdown inhibits the immune activity of B16F10 cell vaccine and anti-melanoma effect, suggesting the MUC1 is an important candidate target antigen of the melanoma vaccine.